Hyperion’s Earnings Call Signals Profitable DeFi Momentum

Eyenovia ((HYPD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Hyperion’s latest earnings call painted an upbeat picture of a business hitting its stride, with management emphasizing strong operational momentum, sharp profit improvement and a fortified balance sheet. While they acknowledged ongoing cash burn, token volatility and regulatory uncertainty, the tone was clearly confident as raised guidance and record profitability signaled growing traction across core DeFi strategies.

Raised 2026 Adjusted Gross Profit Guidance

Hyperion lifted its 2026 adjusted gross profit outlook to $5M–$7M from $4M–$6M, implying about a 20% upgrade and an extra $1M at the midpoint. Management tied the higher bar to accelerating DeFi monetization and the financial flexibility created by a recent $10M equity offering, suggesting stronger conviction in the durability of current trends.

Strong Adjusted Gross Profit Growth

Adjusted gross profit reached roughly $960k in Q1, up 119% from Q3 and 17% sequentially from Q4 as the business scaled beyond its early base. The steady quarter‑over‑quarter climb from $439k to $821k to $960k indicates that multiple revenue levers are contributing, not just one‑off token events.

Segment-Level Growth — DeFi Monetization

DeFi monetization revenue surged to $245k in Q1 from $102k in Q4, a powerful 140% quarter‑over‑quarter jump. The gain was fueled by expanding partnerships, including native Markets and Felix Exchange, plus rising HIP3 market activity and early results from Silhouette testing.

Segment-Level Growth — Yield Enhancement

Yield enhancement strategies delivered $211k in Q1 versus $79k in Q4, a 165% sequential increase that benefited from HYPE token volatility. The formalized partnership with Rysk, which powers premium vault strategies, is turning balance sheet assets into more productive yield generators.

Record GAAP Net Income and Adjusted EBITDA Improvement

Q1 produced record GAAP net income of $8.8M, a stark reversal from the $39.8M net loss in Q4 that underscores the impact of treasury gains and evolving LST accounting. Adjusted EBITDA swung just as dramatically, from a negative $38.9M in Q4 to a positive $19.5M, showcasing a step‑change in underlying profitability metrics.

Treasury and Balance Sheet Strengthening

The company’s treasury has grown meaningfully, with HYPE holdings surpassing 2M tokens by May 11 and the token price climbing from 25.4 at Q4 end to 36.6 in Q1 and 42.2 by May. As a result, HYPE treasury value is about $84.5M versus a $75.9M cash basis, pushing net asset value from $44.2M in Q4 to nearly $90M by mid‑Q2.

Successful Capital Raise & Cash Position

Hyperion completed a $10M public offering, issuing about 2.8M shares for roughly $9M in net proceeds plus additional ATM capital, bolstering liquidity. Cash, equivalents and USDH stood at $9.1M at quarter‑end and rose to around $16M by May 11, giving the company more runway to fund growth and absorb volatility.

Operational Traction on Hyperliquid and Partnerships

On the product side, HIP3 markets now represent about half of daily average trading activity on Hyperliquid, underscoring their central role in the ecosystem. HIP4 launched on May 2 with a Bitcoin outcome market that reportedly saw more than triple the combined launch‑day volume of Polymarket and Kalshi, while partners like Kinetiq and HyperLend are scaling volumes and allocations.

Improved Cash-Realized Profit Mix and Earnings Multiple

The composition of adjusted gross profit is improving, with the cash component rising from 18% in Q3 to 22% in Q4 and 48% in Q1, making earnings quality more tangible. At the same time, the company’s earnings multiple versus a base staking yield expanded from 1.3x to 3.1x, suggesting increasingly efficient use of its crypto assets.

Path to Cash Flow Breakeven

Management reiterated its goal of reaching operating cash flow breakeven by the end of 2026, leaning on growing adjusted gross profit and a tapering legacy biotech cost base. The wind‑down of those older biotech obligations by the end of Q2 is expected to unlock further cost savings and sharpen focus on core DeFi operations.

Volatility and Decline in Ecosystem Awards

Not all revenue lines are on a straight upward path, as ecosystem awards declined to $150k in Q1 from $285k in Q4 and remain inherently lumpy. Management stressed that the timing and size of airdrops or token incentives are unpredictable, making this stream a volatile and less reliable contributor to near‑term results.

HYPE Price Volatility During the Quarter

Although the end‑period HYPE price climbed, the average effective price fell 33% from Q3’s 45.8 to 30.8 in Q1, highlighting meaningful intra‑period swings. That volatility simultaneously creates opportunity for yield strategies and risk for token‑linked revenues and reported valuations, a duality investors must weigh carefully.

Ongoing Operating Cash Burn

Despite the income statement improvements, operating cash flow remained negative, with $4.2M used in Q1 and little change versus Q4, before working capital adjustments. Even excluding a $1.5M build in operating assets, cash burn would still be about $2.7M, underscoring that the journey to self‑funding is still in progress.

Persistent Operating Expense Base

Operating expenses excluding stock‑based compensation dipped only 1% quarter‑over‑quarter to $2.98M, while SG&A ex‑stock comp fell 5% to $2.7M, showing modest cost discipline. Legacy biotech liabilities continue to weigh on the expense base, though management expects this overhang to roll off completely by the end of Q2.

Accounting and Presentation Complexity

The company highlighted shifting GAAP treatment of validator income, which has moved between gross and net presentation as interpretations evolve, complicating comparisons. Heavy reliance on a bespoke adjusted gross profit metric that blends revenue, operating and other income items may make it harder for investors to benchmark against traditional GAAP peers.

Regulatory and Product Uncertainty

Outcome and prediction markets like those built on HIP4 face regulatory questions, with future rule‑making by authorities potentially reshaping how on‑chain markets and vaults can operate. Management acknowledged that adverse regulatory developments could slow product rollouts or limit institutional participation, introducing a significant external risk factor.

Uncertain Monetization of Legacy Biotech Asset

The company’s remaining biotech legacy, the Optejet asset, carries uncertain upside, with executives openly conceding that its eventual value could be zero. Any positive monetization would be a bonus, but investors are being cautioned not to build expectations around a meaningful contribution from this non‑core holding.

Forward-Looking Guidance and Outlook

Looking ahead, Hyperion is signaling confidence by raising its 2026 adjusted gross profit target to $5M–$7M and reaffirming plans for cash‑flow breakeven by year‑end 2026. Management expects continued scaling in staking, validator commissions, yield and DeFi monetization, combined with easing costs, to drive the transition from a high‑growth, cash‑burning model to a sustainably profitable platform.

Hyperion’s earnings call showcased a company gaining real financial traction, powered by DeFi partnerships, growing cash‑based profits and a stronger treasury, even as token volatility and regulation remain watchpoints. For investors, the story now hinges on whether management can convert this momentum and upgraded guidance into durable cash generation while successfully navigating the crypto and regulatory crosscurrents.